QualityStocks News - Zenosense (ZENO) Sensing Growth in 2 Vital Detection Markets

QualityStocks would like to highlight Zenosense, Inc. (OTCQB: ZENO). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

In the company’s news,

Zenosense is continuing to expand its research into key area of bacterial detection. In modern medicine, life and death can be measured in mere days or weeks. Early detection of various cancers and illnesses can often mean a huge difference in survival rates of patients. You may often hear some doctors say that “if you had come in to see me a week later, it might have been too late,” or “if you had come in two weeks sooner, we would have never seen that growth.”

Medical technology has been continuing to evolve to find ways for certain cancers and illnesses to be spotted before a patient enters a doctor’s office for a routine exam. Zenosense, Inc. (OTCQB: ZENO) is one of the one-and-coming early-detection players, and continues to progress toward using exhaled breath as a tool for detection of possible infection or disease.

Zenosense is currently working a couple of devices that will help people use exhaled breath to indicate the presence of MRSA or lung cancer. Research as shown evidence of what are called “markers” that could be found in a person’s exhalations that may suggest the presence of either one of these disorders – potentially sooner than could be found in regular hospital tests. The company recently announced plans to develop a prototype electronic nose device that would be designed to detect lung-cancer markers. The prototype would soon be subject to a clinical trial.

With lung cancer being one of the more common forms of cancer, and with MRSA being very dangerous and deadly due to its antibiotic resistance and propagating ability, any company that is focusing on early detection of either of these illnesses is a company to which one should pay attention. If Zenosense can successfully develop a prototype early-detection device for either or both of these conditions, medicine could be disrupted in ways from which it may never recover. But that can be a strong lead toward establishing better health among patients and fewer hospital visits.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net  

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.